NO960723L - Inhibitorer for TNF-alfa-sekresjon - Google Patents

Inhibitorer for TNF-alfa-sekresjon

Info

Publication number: NO960723L
Authority: NO; Norway
Prior art keywords: tnf; inhibitors; alpha secretion; tace; compounds
Prior art date: 1993-08-23

Application number

NO960723A

Other languages

English (en)

Norwegian (no)

Other versions

NO960723D0 (no

Inventor

Roy Alvin Black

Jeffrey Neal Fitzner

Paul Ronald Sleath

Original Assignee

Immunex Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-08-23

Filing date

1996-02-23

Publication date

1996-02-23

1996-02-23 Application filed by Immunex Corp filed Critical Immunex Corp

1996-02-23 Publication of NO960723D0 publication Critical patent/NO960723D0/no

1996-02-23 Publication of NO960723L publication Critical patent/NO960723L/no

Links

MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 title abstract 2
108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title 1
230000028327 secretion Effects 0.000 title 1
102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 abstract 3
BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
108091007505 ADAM17 Proteins 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
238000003776 cleavage reaction Methods 0.000 abstract 1
-1 hydroxamates Chemical compound 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
125000001151 peptidyl group Chemical group 0.000 abstract 1
239000002243 precursor Substances 0.000 abstract 1
230000007017 scission Effects 0.000 abstract 1
150000003573 thiols Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- C07K5/06095—Arg-amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cardiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Engineering & Computer Science (AREA)
Crystallography & Structural Chemistry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO960723A 1993-08-23 1996-02-23 Inhibitorer for TNF-alfa-sekresjon NO960723L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11060193A	1993-08-23	1993-08-23
US18301994A	1994-01-18	1994-01-18
PCT/US1994/009343 WO1995006031A1 (en)	1993-08-23	1994-08-19	Inhibitors of tnf-alpha secretion

Publications (2)

Publication Number	Publication Date
NO960723D0 NO960723D0 (no)	1996-02-23
NO960723L true NO960723L (no)	1996-02-23

Family

ID=26808203

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO960723A NO960723L (no)	1993-08-23	1996-02-23	Inhibitorer for TNF-alfa-sekresjon

Country Status (8)

Country	Link
EP (1)	EP0715619A4 (fi)
JP (1)	JPH09503201A (fi)
AU (2)	AU687436B2 (fi)
CA (1)	CA2170158A1 (fi)
FI (1)	FI960803L (fi)
NO (1)	NO960723L (fi)
NZ (1)	NZ271893A (fi)
WO (1)	WO1995006031A1 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE179431T1 (de)	1994-10-05	1999-05-15	Darwin Discovery Ltd	Peptidische verbindungen und deren therapeutische verwendung als metalloproteinase-inhibitoren
JPH11504934A (ja) *	1995-05-10	1999-05-11	カイロサイエンス・リミテッド	金属プロテアーゼとｔｎｆの放出を抑制するペプチジル化合物およびその治療的使用
ES2184861T3 (es) *	1995-05-10	2003-04-16	Darwin Discovery Ltd	Compuestos peptidicos inhibidores de la liberacion de la metaloproteinasa y del tnf y su utilizacion terapeutica.
AU706064B2 (en) *	1995-05-10	1999-06-10	Darwin Discovery Limited	Peptide compounds which inhibit metalloproteinase and TNF liberation, and their therapeutic use
US6406901B1 (en)	1995-06-08	2002-06-18	Immunex Corporation	TNF-a converting enzyme
EP0789758A2 (en) *	1995-09-05	1997-08-20	Celltech Therapeutics Limited	Dna sequences coding for a human metalloproteinase and variants thereof
BR9610922A (pt) *	1995-10-05	1999-12-21	Darwin Discovery Ltd	Peptìdios rio-substituìdos como inibidores para metalo-proteinases e liberação de tnf
US5665777A (en) *	1995-11-14	1997-09-09	Abbott Laboratories	Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ATE205184T1 (de)	1995-11-23	2001-09-15	British Biotech Pharm	Metalloproteinase inhibitoren
GB9607120D0 (en) *	1996-04-04	1996-06-12	Chiroscience Ltd	Compounds
US5990293A (en) *	1996-09-05	1999-11-23	Celltech Therapeutics Limited	Human metalloproteinase, variants thereof and DNA sequence coding therefor
US6462023B1 (en)	1996-09-10	2002-10-08	British Biotech Pharmaceuticals, Ltd.	Cytostatic agents
CZ298048B6 (cs)	1996-09-10	2007-06-06	British Biotech Pharmaceuticals Limited	Farmaceutický prostredek a deriváty kyseliny hydroxamové
ZA9818B (en) *	1997-01-07	1998-07-02	Abbott Lab	C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985911A (en) *	1997-01-07	1999-11-16	Abbott Laboratories	C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) *	1997-01-07	1999-09-14	Abbott Laboratories	Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
JP2002516634A (ja) *	1997-06-18	2002-06-04	ザロックフェラーユニヴァーシティ	敗血性ショックおよび実験的関節炎の治療において有用な、抗体およびペプチドの同定方法およびその使用
AU9449398A (en) *	1997-10-10	1999-05-03	Imperial College Innovations Ltd.	Use of csaidtm compounds for the management of uterine contractions
GB9810464D0 (en) *	1998-05-16	1998-07-15	British Biotech Pharm	Hydroxamic acid derivatives
US6329400B1 (en)	1998-08-26	2001-12-11	Glaxo Wellcome Inc.	Formamide compounds as therapeutic agents
US6172064B1 (en)	1998-08-26	2001-01-09	Glaxo Wellcome Inc.	Formamides as therapeutic agents
GB9818605D0 (en)	1998-08-26	1998-10-21	Glaxo Group Ltd	Formamide compounds as therepeutic agents
US6300341B1 (en)	1998-09-30	2001-10-09	The Procter & Gamble Co.	2-substituted heterocyclic sulfonamides
US6307049B1 (en)	1998-09-30	2001-10-23	The Procter & Gamble Co.	Heterocyclic 2-substituted ketoamides
CN1320028A (zh) *	1998-09-30	2001-10-31	宝洁公司	使用磺酰胺治疗脱发的方法
BR9914197A (pt) *	1998-09-30	2001-07-03	Procter & Gamble	Processo de tratamento da perda de cabelos com o uso de cetoamidas
US6288261B1 (en)	1998-12-18	2001-09-11	Abbott Laboratories	Inhibitors of matrix metalloproteinases
US6329550B1 (en)	1998-12-31	2001-12-11	Aventis Pharmaceuticals Inc.	Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
PL350128A1 (en) *	1999-01-13	2002-11-04	Jomaa Pharmaka Gmbh	Use of 3-isoxazolidinones and hydroxylamine acids for the treatment of infections
US20040220103A1 (en)	1999-04-19	2004-11-04	Immunex Corporation	Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) *	1999-09-25	1999-11-24	Smithkline Beecham Biolog	Medical use
WO2002006227A1 (fr) *	2000-07-18	2002-01-24	Chugai Seiyaku Kabushiki Kaisha	Inhibiteurs de la metalloprotease matricielle
AU2002230385A1 (en) *	2000-09-25	2002-04-15	Questcor Pharmaceuticals, Inc.	Peptide deformylase inhibitors
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
BR112021006407A8 (pt)	2018-10-04	2022-12-06	Inst Nat Sante Rech Med	uso de inibidores do egfr para ceratodermas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU596791B2 (en) *	1984-12-19	1990-05-17	Ciba-Geigy Ag	New carbonic acid esters
FR2609289B1 (fr) *	1987-01-06	1991-03-29	Bellon Labor Sa Roger	Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB9102635D0 (en) *	1991-02-07	1991-03-27	British Bio Technology	Compounds
WO1992022523A2 (en) *	1991-06-14	1992-12-23	Research Corporation Technologies, Inc.	Peptide derivatives of collagenase inhibitor
GB9215665D0 (en) *	1992-07-23	1992-09-09	British Bio Technology	Compounds
GB9323165D0 (en) *	1993-11-10	1994-01-05	Chiros Ltd	Compounds
GB9411088D0 (en) *	1994-06-03	1994-07-27	Hoffmann La Roche	Hydroxylamine derivatives

1994
- 1994-08-19 NZ NZ271893A patent/NZ271893A/en unknown
- 1994-08-19 WO PCT/US1994/009343 patent/WO1995006031A1/en not_active Application Discontinuation
- 1994-08-19 EP EP94925940A patent/EP0715619A4/en not_active Ceased
- 1994-08-19 JP JP7507668A patent/JPH09503201A/ja active Pending
- 1994-08-19 CA CA002170158A patent/CA2170158A1/en not_active Abandoned
- 1994-08-19 AU AU75694/94A patent/AU687436B2/en not_active Ceased
1996
- 1996-02-22 FI FI960803A patent/FI960803L/fi unknown
- 1996-02-23 NO NO960723A patent/NO960723L/no unknown
1998
- 1998-01-06 AU AU50302/98A patent/AU5030298A/en not_active Abandoned

Also Published As

Publication number	Publication date
AU7569494A (en)	1995-03-21
NO960723D0 (no)	1996-02-23
NZ271893A (en)	1997-11-24
JPH09503201A (ja)	1997-03-31
AU687436B2 (en)	1998-02-26
FI960803A0 (fi)	1996-02-22
AU5030298A (en)	1998-03-05
WO1995006031A1 (en)	1995-03-02
CA2170158A1 (en)	1995-03-02
FI960803L (fi)	1996-04-22
EP0715619A4 (en)	1997-03-19
EP0715619A1 (en)	1996-06-12

Publication	Publication Date	Title
NO960723L (no)	1996-02-23	Inhibitorer for TNF-alfa-sekresjon
MY129998A (en)	2007-05-31	Saccharin derivative proteolytic enzyme inhibitors
Harris et al.	1997	Pseudosubstrate inhibition of cyclic AMP-dependent protein kinase in intact pancreatic islets: effects on cyclic AMP-dependent and glucose-dependent insulin secretion
MX9207449A (es)	1994-03-31	Inhibidores de la enzima proteolitica derivada de sacarina.
HUP0102250A2 (hu)	2001-11-28	Nemstabilis dipeptidilpeptidáz IV-gátlók vegyületei, azokat tartalmazó gyógyászati készítmények és alkalmazásuk
NO20051788L (no)	2005-06-13	Hydantoinderivater og deres anvendelse som TACE-inhibitorer
DK0544777T3 (da)	1994-08-22	Enzymatisk detergentsammensætning og fremgangsmåde til enzymstabilisering
AU2003282920A1 (en)	2004-05-04	Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
BG103977A (en)	2000-11-30	Low molecular rotamase enzymic activity inhibitors
BG104780A (en)	2001-10-31	Inhibitors of phospholipase enzymes
AU2002357312A1 (en)	2003-07-09	Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
AU2002341715A1 (en)	2003-04-01	Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
MY135732A (en)	2008-06-30	5,6-trimethylenepyrimidin - 4 - one compounds
NO961888L (no)	1996-05-09	Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
AU2001248701A1 (en)	2001-10-03	Inhibitors of histone deacetylase
DK0719154T3 (da)	2001-11-26	Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
MY100641A (en)	1990-12-29	Neutral metalloendopeptidase inhibitors in the treatment of hypertension.
NZ503962A (en)	2002-03-28	ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
van der Zee et al.	1996	Cytokine‐induced endogenous procollagenase stored in the extracellular matrix of soft connective tissue results in a burst of collagen breakdown following its activation
NO914217L (no)	1991-10-28	Sakkarinderivater nyttige som proteolytiske enzyminhibitorer og fremstilling derav
NO971444L (no)	1997-05-26	Inhibitor av stamcelle-proliferasjon og anvendelser derav
WO2004052236A3 (en)	2004-08-26	Methods and compositions for treatment of otitis media
AU2002325782A1 (en)	2004-01-06	Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
BR0213994A (pt)	2004-08-31	Derivados heterocìclicos de glicinamida e seus usos médicos
DE59009945D1 (de)	1996-01-18	Mittel zur hemmung von hiv-proteasen.